Investigating Differential Changes in Cardiovascular Mortality by Documented diabetes in the United States Before and During the COVID-19 Pandemic: A Comparative Time-Series Analysis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Whether diabetes modified pandemic-related changes in cardiovascular disease (CVD) mortality remains uncertain. We examined differential changes in US CVD mortality among deaths with versus without diabetes documented on the death certificate.
Methods
We analyzed CDC WONDER Multiple Cause of Death data from 2005 to 2024, identifying deaths with CVD as the underlying cause among adults aged ≥25 years. Cohorts were CVD deaths with diabetes documented as a contributing cause (CVD+DM) and CVD deaths without documented diabetes. Because pre-2020 trajectories differed, the primary comparison of age-adjusted rates used a comparative interrupted time-series model allowing cohort-specific pre-2020 trends. Difference-in-differences estimates (2015–2019 vs 2020–2024) were descriptive.
Results
CVD+DM mortality declined from 43.1 per 100,000 in 2005 to 34.3 in 2019 and was 38.4 in 2024; mortality without documented diabetes declined from 398.7 to 296.6 and was 289.8. In the primary analysis, CVD+DM mortality showed a 13.1% greater relative level increase at 2020 (95% CI, 10.4%–15.9%), with no significant differential change in slope thereafter. Descriptively, the ratio of rate ratios was 1.16, and the absolute difference-in-differences was 5.0 per 100,000.
Conclusions
After accounting for cohort-specific pre-2020 trends, CVD mortality with documented diabetes showed a greater relative increase at the 2020 transition. These findings describe differential mortality patterns rather than a causal effect of diabetes or the pandemic.
WHAT IS NEW?
-
Cardiovascular disease mortality with documented diabetes showed a 13% greater relative level increase at the 2020 transition than cardiovascular disease mortality without documented diabetes, after accounting for pre-2020 trends.
-
The difference was concentrated in the level change around 2020, with no significant differential change in slope thereafter.
-
Findings were directionally consistent across analyses using alternative baseline periods, breakpoints, and restriction to type 2 diabetes.
WHAT ARE THE CLINICAL IMPLICATIONS?
-
The findings suggest that people with coexisting cardiovascular disease and diabetes may warrant particular attention during periods of major health system disruption, including efforts to maintain continuity of cardiometabolic care.
-
Because the analysis is based on death-certificate documentation, the findings should be interpreted as a population-level mortality signal rather than evidence that diabetes caused the observed mortality difference.